

Andrew A Nierenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8568367/publications.pdf>

Version: 2024-02-01

195
papers

5,690
citations

100601

38
h-index

107981

68
g-index

206
all docs

206
docs citations

206
times ranked

6229
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a model to predict psychotherapy response for depression among Veterans. <i>Psychological Medicine</i> , 2023, 53, 3591-3600.	2.7	4
2	Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes. <i>Australian and New Zealand Journal of Psychiatry</i> , 2023, 57, 93-103.	1.3	3
3	Adrift in time: the subjective experience of circadian challenge during COVID-19 amongst people with mood disorders. <i>Chronobiology International</i> , 2022, 39, 57-67.	0.9	5
4	Cardiometabolic risk markers during mood-stabilizing treatment: Correlation with drug-specific effects, depressive symptoms and treatment response. <i>Journal of Affective Disorders</i> , 2022, 300, 41-49.	2.0	6
5	Estimating the symptom structure of bipolar disorder via network analysis: Energy dysregulation as a central symptom.. , 2022, 131, 86-97.		18
6	Reports of the demise of CBT for bipolar disorder have been greatly exaggerated: a response to Samama. <i>Bipolar Disorders</i> , 2022, 24, 472-473.	1.1	0
7	Childhood trauma and treatment outcomes during mood-stabilising treatment with lithium or quetiapine among outpatients with bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2022, 145, 615-627.	2.2	9
8	Predictors of functional impairment in bipolar disorder: Results from 13 cohorts from seven countries by the global bipolar cohort collaborative. <i>Bipolar Disorders</i> , 2022, 24, 709-719.	1.1	16
9	Strategies and foundations for scientific discovery in longitudinal studies of bipolar disorder. <i>Bipolar Disorders</i> , 2022, 24, 499-508.	1.1	15
10	C-reactive protein and affective inhibition in bipolar disorder. <i>Journal of Affective Disorders</i> , 2022, 306, 39-46.	2.0	1
11	Physical exercise for bipolar disorder: Time for action. <i>Bipolar Disorders</i> , 2022, 24, 324-325.	1.1	2
12	Genetic Association of Attention-Deficit/Hyperactivity Disorder and Major Depression With Suicidal Ideation and Attempts in Children: The Adolescent Brain Cognitive Development Study. <i>Biological Psychiatry</i> , 2022, 92, 236-245.	0.7	17
13	Association of Early Life Prescriptions for Antibiotics and Acid Suppressants with Childhood Psychotropic Prescriptions. <i>Journal of Pediatrics</i> , 2022, , .	0.9	1
14	Patterns and correlates of patient-reported helpfulness of treatment for common mental and substance use disorders in the WHO World Mental Health Surveys. <i>World Psychiatry</i> , 2022, 21, 272-286.	4.8	16
15	Social Rhythm Disruption is Associated with Greater Depressive Symptoms in People with Mood Disorders: Findings from a Multinational Online Survey During COVID-19. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 832-841.	0.9	6
16	Web-Based Mindfulness-Based Interventions for Well-being: Randomized Comparative Effectiveness Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e35620.	2.1	2
17	Adjunctive antidepressant treatment among 763 outpatients with bipolar disorder: Findings from the Bipolar CHOICE and LITMUS trials. <i>Depression and Anxiety</i> , 2021, 38, 114-123.	2.0	5
18	A taxonomy of clinical response to mood stabilizers. <i>Bipolar Disorders</i> , 2021, 23, 24-32.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressive disorder and chronic inflammation. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2021, 164, 102219.	1.0	37
20	Association Between Care Utilization and Anxiety Outcomes in an On-Demand Mental Health System: Retrospective Observational Study. <i>JMIR Formative Research</i> , 2021, 5, e24662.	0.7	14
21	Wrestling With Antidepressant Use in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	4
22	Clinimetric Criteria for Patient-Reported Outcome Measures. <i>Psychotherapy and Psychosomatics</i> , 2021, 90, 222-232.	4.0	84
23	A surrogate measure for patient reported symptom remission in administrative data. <i>BMC Psychiatry</i> , 2021, 21, 121.	1.1	4
24	Evidence-based versus clinical expertise guidelines for Bipolar Disorders. <i>Bipolar Disorders</i> , 2021, 23, 509-510.	1.1	0
25	Perceived helpfulness of bipolar disorder treatment: Findings from the World Health Organization World Mental Health Surveys. <i>Bipolar Disorders</i> , 2021, 23, 565-583.	1.1	7
26	How to Evaluate Patients and Educate Them About Self-Examinations for Tardive Dyskinesia Between Appointments. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	1
27	Psychotic symptoms during bipolar depressive episodes and suicidal ideation. <i>Journal of Affective Disorders</i> , 2021, 282, 1241-1246.	2.0	4
28	Precision Psychiatry and a Vision for the Future. <i>Psychiatric Annals</i> , 2021, 51, 206-206.	0.1	1
29	An online intervention for increasing physical activity in individuals with mood disorders at risk for cardiovascular disease: Design considerations. <i>Journal of Affective Disorders</i> , 2021, 291, 102-109.	2.0	7
30	Illness stage and predominant polarity in bipolar disorder: Correlation with burden of illness and moderation of treatment outcome. <i>Journal of Psychiatric Research</i> , 2021, 140, 205-213.	1.5	5
31	Statins: Neurobiological underpinnings and mechanisms in mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 693-708.	2.9	15
32	Response and remission rates during 24 weeks of mood-stabilizing treatment for bipolar depression depending on early non-response. <i>Psychiatry Research</i> , 2021, 305, 114194.	1.7	1
33	Cigarette smokers with a mood symptom history enrolled in a physical activity trial. <i>Bipolar Disorders</i> , 2021, 23, 842-843.	1.1	0
34	Universal depression prevention: An umbrella review of meta-analyses. <i>Journal of Psychiatric Research</i> , 2021, 144, 483-493.	1.5	18
35	FMT for psychiatric disorders: Following the brown brick road into the future. <i>Bipolar Disorders</i> , 2021, 23, 651-655.	1.1	8
36	Dimensional Neural Markers of Affective Processing in Bipolar Disorder. <i>Psychiatry Research</i> , 2021, 307, 114304.	1.7	0

#	ARTICLE	IF	CITATIONS
37	Lessons learned: Building a coalition to advance equity in cancer and mental health care. <i>Psycho-Oncology</i> , 2021, 30, 2087-2091.	1.0	1
38	The impact of binge eating behavior on lithium- and quetiapine-associated changes in body weight, body mass index, and waist circumference during 6 months of treatment: Findings from the bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2020, 266, 772-781.	2.0	13
39	Predictive factors of diagnostic conversion from major depressive disorder to bipolar disorder in young adults ages 19â€³34: A nationwide population study in South Korea. <i>Journal of Affective Disorders</i> , 2020, 265, 52-58.	2.0	13
40	Bipolar disorders. <i>Lancet</i> , The, 2020, 396, 1841-1856.	6.3	419
41	Dose-Dependent Effects of EPA Supplementation on Plasma Specialized Pro-Resolving Mediators in Major Depressive Disorder Patients with Chronic Inflammation. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa068_023.	0.1	0
42	Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than <i>Clostridium difficile</i> infection: a systematic review and meta-analysis. <i>Gut Microbes</i> , 2020, 12, 1854640.	4.3	81
43	Assessment of Behavioral Health Services Use Among Low-Income Medicare Beneficiaries After Reductions in Coinsurance Fees. <i>JAMA Network Open</i> , 2020, 3, e2019854.	2.8	3
44	Preliminary findings on topiramate for addressing health behaviors in comorbid bipolar disorder and alcohol use disorder. <i>Psychiatry Research</i> , 2020, 289, 113037.	1.7	0
45	An evaluation of suicidal risk in bipolar patients with comorbid posttraumatic stress disorder. <i>Journal of Affective Disorders</i> , 2020, 266, 49-56.	2.0	7
46	20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings. <i>American Journal of Psychiatry</i> , 2020, 177, 706-715.	4.0	133
47	Targeting Mitochondrial Dysfunction for Bipolar Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 48, 61-99.	0.8	10
48	Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. <i>Journal of Affective Disorders</i> , 2020, 273, 131-137.	2.0	7
49	Clinical Correlates of False Positive Assignment in Bipolar Screening Measures Across Psychiatric Diagnoses among Patients without Bipolar Disorder. <i>Psychiatry Investigation</i> , 2020, 17, 1118-1125.	0.7	2
50	How to Evaluate Patients for Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2020, 82, .	1.1	0
51	Collaborating With Patients to Make Treatment Decisions Based on Benefits and Risks of Medications Associated With Tardive Dyskinesia. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	1
52	Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management. <i>Bipolar Disorders</i> , 2019, 21, 650-659.	1.1	19
53	Bipolar II Disorder Is NOT a Myth. <i>Canadian Journal of Psychiatry</i> , 2019, 64, 537-540.	0.9	7
54	Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. <i>Journal of Affective Disorders</i> , 2019, 257, 17-22.	2.0	26

#	ARTICLE	IF	CITATIONS
55	Clinical applications of transcranial magnetic stimulation in bipolar disorder. <i>Brain and Behavior</i> , 2019, 9, e01419.	1.0	32
56	Bipolar depression and suicidal ideation: Moderators and mediators of a complex relationship. <i>Journal of Affective Disorders</i> , 2019, 259, 164-172.	2.0	13
57	Evolving Issues in the Treatment of Depression. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2401.	3.8	12
58	Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials. <i>Acta Neuropsychiatrica</i> , 2019, 31, 230-234.	1.0	2
59	Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and network meta-analysis. <i>BMJ Open</i> , 2019, 9, e027574.	0.8	18
60	Transcranial magnetic stimulation in anxiety and trauma-related disorders: A systematic review and meta-analysis. <i>Brain and Behavior</i> , 2019, 9, e01284.	1.0	94
61	Pilot study of a lifestyle intervention for bipolar disorder: Nutrition exercise wellness treatment (NEW Tx). <i>Journal of Affective Disorders</i> , 2019, 250, 278-283.	2.0	24
62	Faecal microbiota transplants for depression – Who gives a crapsule?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 732-734.	1.3	13
63	Predictive modeling for response to lithium and quetiapine in bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 428-436.	1.1	15
64	Bridge: Person-Centered Collaborative Care for Patients with Serious Mental Illness and Cancer. <i>Oncologist</i> , 2019, 24, 901-910.	1.9	46
65	Objective smartphone data as a potential diagnostic marker of bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2019, 53, 171-172.	1.3	1
66	Comorbid anxiety in bipolar CHOICE: Insights from the bipolar inventory of symptoms scale. <i>Journal of Affective Disorders</i> , 2019, 246, 126-131.	2.0	11
67	The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. <i>Journal of Affective Disorders</i> , 2019, 246, 217-223.	2.0	7
68	Statin treatment and the risk of depression. <i>Journal of Affective Disorders</i> , 2019, 246, 706-715.	2.0	31
69	Deficits in frontoparietal activation and anterior insula functional connectivity during regulation of cognitive-affective interference in bipolar disorder. <i>Bipolar Disorders</i> , 2019, 21, 244-258.	1.1	43
70	Tachyphylaxis in major depressive disorder: A review of the current state of research. <i>Journal of Affective Disorders</i> , 2019, 245, 488-497.	2.0	23
71	The Adult ADHD Quality Measures Initiative. <i>Journal of Attention Disorders</i> , 2019, 23, 1063-1078.	1.5	15
72	Substance use comorbidity in bipolar disorder: A qualitative review of treatment strategies and outcomes. <i>American Journal on Addictions</i> , 2018, 27, 188-201.	1.3	28

#	ARTICLE	IF	CITATIONS
73	Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha as a Novel Target for Bipolar Disorder and Other Neuropsychiatric Disorders. <i>Biological Psychiatry</i> , 2018, 83, 761-769.	0.7	64
74	Treatment outcomes of acute bipolar depressive episode with psychosis. <i>Depression and Anxiety</i> , 2018, 35, 402-410.	2.0	9
75	Memory performance predicts response to psychotherapy for depression in bipolar disorder: A pilot randomized controlled trial with exploratory functional magnetic resonance imaging. <i>Journal of Affective Disorders</i> , 2018, 229, 342-350.	2.0	10
76	Medication disposal practices: Increasing patient and clinician education on safe methods. <i>Journal of International Medical Research</i> , 2018, 46, 927-939.	0.4	44
77	Sleep disturbance may impact treatment outcome in bipolar disorder: A preliminary investigation in the context of a large comparative effectiveness trial. <i>Journal of Affective Disorders</i> , 2018, 225, 563-568.	2.0	18
78	Decreased activation and subsyndromal manic symptoms predict lower remission rates in bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 994-1002.	1.3	3
79	MoodNetwork. <i>Medical Care</i> , 2018, 56, S48-S52.	1.1	13
80	Applying Association Rules to Study Bipolar Disorder and Premenstrual Dysphoric Disorder Comorbidity. , 2018, , .		3
81	Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 21, 350-360.	1.1	5
82	The impact of substance use disorders on recovery from bipolar depression: Results from the Systematic Treatment Enhancement Program for Bipolar Disorder psychosocial treatment trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 847-855.	1.3	9
83	Intrinsic functional neurocircuitry associated with treatment response to transdiagnostic CBT in bipolar disorder with anxiety. <i>Journal of Affective Disorders</i> , 2018, 238, 383-391.	2.0	13
84	Prevalence and predictors of physician recommendations for medication adjustment in bipolar disorder treatment. <i>Journal of Affective Disorders</i> , 2018, 238, 666-673.	2.0	4
85	Revisiting the Abnormal Involuntary Movement Scale. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	32
86	Randomized trial protocol of bridge intervention for patients with serious mental illness and cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 153-153.	0.8	0
87	White blood cell count correlates with mood symptom severity and specific mood symptoms in bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 355-365.	1.3	22
88	Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. <i>Depression and Anxiety</i> , 2017, 34, 281-290.	2.0	12
89	Dialectical Behavior Therapy Group Skills Training for Bipolar Disorder. <i>Behavior Therapy</i> , 2017, 48, 557-566.	1.3	46
90	Bipolar mixed features â€œ Results from the comparative effectiveness for bipolar disorder (Bipolar) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.0	10

#	ARTICLE	IF	CITATIONS
91	Transdiagnostic treatment of bipolar disorder and comorbid anxiety using the Unified Protocol for Emotional Disorders: A pilot feasibility and acceptability trial. <i>Journal of Affective Disorders</i> , 2017, 219, 209-221.	2.0	44
92	“Mood stabilizers”™ as the royal road to nirvana or a narrow bridge to well-being?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 939-940.	1.3	0
93	Clinical correlates of acute bipolar depressive episode with psychosis. <i>Journal of Affective Disorders</i> , 2017, 217, 29-33.	2.0	19
94	Poor quality of life and functioning in bipolar disorder. <i>International Journal of Bipolar Disorders</i> , 2017, 5, 10.	0.8	63
95	Illness severity and biomarkers in depression: Using a unidimensional rating scale to examine BDNF. <i>Comprehensive Psychiatry</i> , 2017, 75, 46-52.	1.5	18
96	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2017, 223, 146-152.	2.0	18
97	L-Methylfolate For Bipolar I depressive episodes: An open trial proof-of-concept registry. <i>Journal of Affective Disorders</i> , 2017, 207, 429-433.	2.0	18
98	Behavioral Indicators on a Mobile Sensing Platform Predict Clinically Validated Psychiatric Symptoms of Mood and Anxiety Disorders. <i>Journal of Medical Internet Research</i> , 2017, 19, e75.	2.1	101
99	Testing for clinical inertia in medication treatment of bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 205, 13-19.	2.0	4
100	The Effect of Concomitant Treatment With SSRIs and Statins: A Population-Based Study. <i>American Journal of Psychiatry</i> , 2016, 173, 807-815.	4.0	63
101	Empirically supported psychosocial interventions for bipolar disorder: Current state of the research. <i>Journal of Affective Disorders</i> , 2016, 201, 203-214.	2.0	63
102	Tracking medication changes to assess outcomes in comparative effectiveness research: A bipolar CHOICE study. <i>Journal of Affective Disorders</i> , 2016, 205, 159-164.	2.0	7
103	Cognitive Remediation and Bias Modification Strategies in Mood and Anxiety Disorders. <i>Current Behavioral Neuroscience Reports</i> , 2016, 3, 340-349.	0.6	8
104	A cluster analytic approach to identifying predictors and moderators of psychosocial treatment for bipolar depression: Results from STEP-BD. <i>Journal of Affective Disorders</i> , 2016, 203, 152-157.	2.0	9
105	Medical burden, body mass index and the outcome of psychosocial interventions for bipolar depression. <i>Australian and New Zealand Journal of Psychiatry</i> , 2016, 50, 667-677.	1.3	16
106	A randomized, placebo-controlled proof-of-concept trial of adjunctive topiramate for alcohol use disorders in bipolar disorder. <i>American Journal on Addictions</i> , 2016, 25, 94-98.	1.3	24
107	Patient perceptions of physical health and bipolar symptoms: The intersection of mental and physical health. <i>Journal of Affective Disorders</i> , 2016, 189, 203-206.	2.0	18
108	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. <i>Journal of Affective Disorders</i> , 2016, 192, 212-218.	2.0	22

#	ARTICLE	IF	CITATIONS
109	Relationship between placebo response rate and clinical trial outcome in bipolar depression. <i>Journal of Psychiatric Research</i> , 2016, 74, 38-44.	1.5	17
110	Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness). <i>Journal of Clinical Psychiatry</i> , 2016, 77, 90-99.	1.1	69
111	Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder. <i>Psychiatry Investigation</i> , 2016, 13, 321.	0.7	18
112	A latent class analysis of parental bipolar disorder: Examining associations with offspring psychopathology. <i>Psychiatry Research</i> , 2015, 230, 314-322.	1.7	5
113	Getting to wellness: The potential of the athletic model of marginal gains for the treatment of bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 1207-1214.	1.3	21
114	Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. <i>Psychiatry Journal</i> , 2015, 2015, 1-8.	0.7	90
115	Psychotherapy use in bipolar disorder: Association with functioning and illness severity. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 453-461.	1.3	21
116	Eating behavior and obesity in bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 566-572.	1.3	17
117	Family functioning in the context of parental bipolar disorder: Associations with offspring age, sex, and psychopathology.. <i>Journal of Family Psychology</i> , 2015, 29, 108-118.	1.0	17
118	An exploratory study of responses to low-dose lithium in African Americans and Hispanics. <i>Journal of Affective Disorders</i> , 2015, 178, 224-228.	2.0	9
119	Screening for Suicide Risk in the College Population. <i>Journal of Rational - Emotive and Cognitive - Behavior Therapy</i> , 2015, 33, 78-94.	1.0	17
120	Predictors of placebo response in bipolar depression. <i>International Clinical Psychopharmacology</i> , 2015, 30, 59-66.	0.9	18
121	Anxiety symptoms are linked to new-onset suicidal ideation after six months of follow-up in outpatients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2015, 187, 183-187.	2.0	26
122	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2015, 71, 126-133.	1.5	32
123	What Happens Now? The Importance of Naturalistic Course After First Mania. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1161-e1163.	1.1	0
124	Improving the Care of Patients Who Have Treatment-Resistant Depression: The Promise of the PCORnet Mood Network. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e528-e530.	1.1	0
125	The effect of personalized guideline-concordant treatment on quality of life and functional impairment in bipolar disorder. <i>Journal of Affective Disorders</i> , 2014, 169, 144-148.	2.0	15
126	A novel application of the <i>Intent to Attend</i> assessment to reduce bias due to missing data in a randomized controlled clinical trial. <i>Clinical Trials</i> , 2014, 11, 494-502.	0.7	9

#	ARTICLE	IF	CITATIONS
127	Thyroid stimulating hormone and serum, plasma, and platelet brain-derived neurotrophic factor during a 3-month follow-up in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 169, 112-117.	2.0	20
128	A Novel Home Sleep Monitoring Device and Brief Sleep Intervention for Bipolar Disorder: Feasibility, Tolerability, and Preliminary Effectiveness. <i>Cognitive Therapy and Research</i> , 2014, 38, 55-61.	1.2	11
129	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. <i>Journal of Affective Disorders</i> , 2014, 161, 30-35.	2.0	18
130	Correlates of real world executive dysfunction in bipolar I disorder. <i>Journal of Psychiatric Research</i> , 2014, 53, 87-93.	1.5	27
131	Clinical applications of herbal medicines for anxiety and insomnia; targeting patients with bipolar disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2014, 48, 705-715.	1.3	22
132	Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 114-127.	0.7	60
133	Methodological approaches and magnitude of the clinical unmet need associated with amotivation in mood disorders. <i>Journal of Affective Disorders</i> , 2014, 168, 439-451.	2.0	43
134	Serum lipids, recent suicide attempt and recent suicide status in patients with major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 51, 113-118.	2.5	70
135	Association of exercise with quality of life and mood symptoms in a comparative effectiveness study of bipolar disorder. <i>Journal of Affective Disorders</i> , 2013, 151, 722-727.	2.0	76
136	Lithium Treatment Moderate-Dose Use Study (LiTMUS) for Bipolar Disorder: A Randomized Comparative Effectiveness Trial of Optimized Personalized Treatment With and Without Lithium. <i>American Journal of Psychiatry</i> , 2013, 170, 102-110.	4.0	80
137	Nutrition, Exercise, and Wellness Treatment in bipolar disorder: proof of concept for a consolidated intervention. <i>International Journal of Bipolar Disorders</i> , 2013, 1, 24.	0.8	65
138	Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 26-42.	1.3	61
139	The absence of depressive symptoms is not the presence of wellness: Validation of the Clinical Positive Affect Scale. <i>Australian and New Zealand Journal of Psychiatry</i> , 2012, 46, 1165-1172.	1.3	21
140	Are We Losing Our Minds?. <i>CNS Spectrums</i> , 2010, 15, 416-417.	0.7	0
141	My Mother's Levetiracetam. <i>CNS Spectrums</i> , 2010, 15, 487-488.	0.7	0
142	Deficits in Psychological Well-being and Quality of Life in Minor Depression: Implications for DSM-IV. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 208-216.	1.9	41
143	Switch or augment? Lessons from STAR*D. <i>Annals of Clinical Psychiatry</i> , 2010, 22, S4-8.	0.6	3
144	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009, 43, 956-967.	1.3	9

#	ARTICLE	IF	CITATIONS
145	Lithium treatment " moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. <i>Clinical Trials</i> , 2009, 6, 637-648.	0.7	39
146	Lessons from STEP-BD for the treatment of bipolar depression. <i>Depression and Anxiety</i> , 2009, 26, 106-109.	2.0	16
147	Major Depressive Disorder: Barriers to Treatment. <i>CNS Spectrums</i> , 2009, 14, 5-7.	0.7	51
148	What Have We Learned About Bipolar Disorder From STEP-BD and Other Practical Trials?. <i>Journal of Clinical Psychiatry</i> , 2009, 70, e30.	1.1	1
149	Vagus Nerve Stimulation: 2-Year Outcomes for Bipolar Versus Unipolar Treatment-Resistant Depression. <i>Biological Psychiatry</i> , 2008, 64, 455-460.	0.7	83
150	Critical Thinking about Adverse Drug Effects: Lessons from the Psychology of Risk and Medical Decision-Making for Clinical Psychopharmacology. <i>Psychotherapy and Psychosomatics</i> , 2008, 77, 201-208.	4.0	13
151	Major Depressive Disorder: <i>Epidemiology, Course of Illness, and Treatment</i>. <i>CNS Spectrums</i> , 2008, 13, 4-7.	0.7	4
152	A Brief Review of Antidepressant Efficacy, Effectiveness, Indications, and Usage for Major Depressive Disorder. <i>Journal of Occupational and Environmental Medicine</i> , 2008, 50, 428-436.	0.9	54
153	Effective Agents in Treating Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2008, 69, e29.	1.1	4
154	An analysis of the efficacy of treatments for bipolar depression. <i>Journal of Clinical Psychiatry</i> , 2008, 69 Suppl 5, 4-8.	1.1	3
155	Combined olanzapine plus fluoxetine modestly improves symptoms of acute bipolar I depression compared to lamotrigine. <i>Evidence-Based Mental Health</i> , 2007, 10, 12-12.	2.2	3
156	Psychosocial Treatments for Bipolar Depression. <i>Archives of General Psychiatry</i> , 2007, 64, 419.	13.8	485
157	Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. <i>Current Medical Research and Opinion</i> , 2007, 23, 401-416.	0.9	127
158	A Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression. <i>Psychiatric Clinics of North America</i> , 2007, 30, 13-29.	0.7	39
159	Family history of mood disorder and characteristics of major depressive disorder: A STAR—D (sequenced treatment alternatives to relieve depression) study. <i>Journal of Psychiatric Research</i> , 2007, 41, 214-221.	1.5	67
160	A contribuiçŁo de ensaios clĒnicos em psiquiatria: para alĒm da ciĒncia bĒsica. <i>Revista De Psiquiatria Do Rio Grande Do Sul</i> , 2007, 29, 13-14.	0.3	1
161	A counter proposal to manage financial conflicts of interest in academic psychiatry. <i>World Psychiatry</i> , 2007, 6, 34-6.	4.8	3
162	Revisiting the Clinical Utility of Cytochrome p450 in Practice. <i>Psychiatry</i> , 2007, 4, 28-30.	0.3	0

#	ARTICLE	IF	CITATIONS
163	A Comparison of Lithium and T ₃ Augmentation Following Two Failed Medication Treatments for Depression: A STAR*D Report. American Journal of Psychiatry, 2006, 163, 1519-1530.	4.0	526
164	Treatment-Resistant Bipolar Depression: A STEP-BD Equipose Randomized Effectiveness Trial of Antidepressant Augmentation With Lamotrigine, Inositol, or Risperidone. American Journal of Psychiatry, 2006, 163, 210-216.	4.0	218
165	The integration of measurement and management for the treatment of bipolar disorder: a STEP-BD model of collaborative care in psychiatry. Journal of Clinical Psychiatry, 2006, 67 Suppl 11, 3-7.	1.1	6
166	Placebo-Controlled Continuation Treatment with Mirtazapine: Acute Pattern of Response Predicts Relapse. Neuropsychopharmacology, 2004, 29, 1012-1018.	2.8	45
167	Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. Journal of Psychiatric Research, 2004, 38, 583-589.	1.5	25
168	Predictors of response to antidepressants. Psychiatric Clinics of North America, 2003, 26, 345-352.	0.7	78
169	Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants. Journal of Clinical Psychopharmacology, 2003, 23, 92-95.	0.7	90
170	Nortriptyline for Treatment-Resistant Depression. Journal of Clinical Psychiatry, 2003, 64, 35-39.	1.1	139
171	Prevention of relapse and recurrence in depression: the role of long-term pharmacotherapy and psychotherapy. Journal of Clinical Psychiatry, 2003, 64 Suppl 15, 13-7.	1.1	23
172	Body dysmorphic disorder in outpatients with major depression. Journal of Affective Disorders, 2002, 69, 141-148.	2.0	57
173	Immunologic factors in treatment-resistant depression. , 2001, , 142-156.		0
174	Psychiatric comorbidity in treatment-resistant depression. , 2001, , 430-478.		2
175	The characterization and definition of treatment-resistant mood disorders. , 2001, , 3-29.		13
176	Overview of treatment-resistant depression and its management. , 2001, , 30-46.		6
177	Psychoneuroendocrine aspects of treatment-resistant mood disorders. , 2001, , 49-79.		0
178	Estrogen and depressive illness in women. , 2001, , 80-95.		0
179	Sleep abnormalities in treatment-resistant mood disorders. , 2001, , 96-110.		6
180	Structural and functional brain imaging in treatment-resistant depression. , 2001, , 111-141.		0

#	ARTICLE	IF	CITATIONS
181	Selective serotonin reuptake inhibitors and serotonin/norepinephrine reuptake inhibitors in treatment-resistant depression. , 2001, , 159-179.		0
182	Conventional and second generation monoamine oxidase inhibitors in treatment-resistant depression. , 2001, , 180-193.		0
183	Drug combination strategies. , 2001, , 194-222.		6
184	Electroconvulsive therapy in medication-resistant depression. , 2001, , 223-238.		5
185	Thyroid augmentation. , 2001, , 239-251.		1
186	Cognitive therapy and psychosocial interventions in chronic and treatment-resistant mood disorders. , 2001, , 252-270.		0
187	Chronic and refractory mood disorders in childhood and adolescence. , 2001, , 273-287.		2
188	Treatment-resistant depression in the elderly. , 2001, , 288-320.		1
189	Management of treatment-resistant depression during pregnancy and the postpartum period. , 2001, , 321-349.		0
190	Preliminary algorithms for treatment-resistant bipolar depression. , 2001, , 350-404.		2
191	Medical disorders and treatment-resistant depression. , 2001, , 405-429.		4
192	Suicide in treatment-refractory depression. , 2001, , 479-488.		1
193	The economic impact of treatment non-response in major depressive disorders. , 2001, , 491-503.		1
194	Ethical issues in research and treatment of patients with mood disorders. , 2001, , 504-516.		0
195	Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians. Canadian Journal of Psychiatry, 2000, 45, 476-481.	0.9	69